Industry Experts

Dolly Parasrampuria has almost 25 years of experience in clinical drug development from first-in-human studies through global approvals of several small molecules and biologics across multiple therapeutic areas. She has contributed, as the lead clinical pharmacologist, to the development and approval for several marketed products that include oncology, rare and pediatric diseases. Currently, she is an Executive Director/Head of Clinical Pharmacology for Gene and Cell Therapy and Biopharma products at Astellas.

Dolly earned her PhD from the University of California in San Francisco UCSF and has Bachelor’s and Master’s degrees in Pharmacy from the Birla Institute of Technology & Science in Pilani, India (BITS-Pilani). She has over 70 publications and two issued patents and has served as the Editorial Board member for the Journal of Clinical Pharmacology from 2002 to 2017, and as Chair and Vice Chair for Pharmacometrics & Biostatistics Sections for the American Society for Clinical Pharmacology & Therapeutics from 2004 to 2007. She was appointed to the Bio-Industry Committee for American Society for Gene and Cell Therapy for the May 2023-2026 term. Dolly is passionate about promoting innovation and global development of novel therapeutics that improve the quality of life of patients.